Cyclin-dependent kinase 9 (CDK9) can predict the prognosis of osteosarcoma, bladder cancer and other tumors, and can be used for targeted treatment of glioblastoma (Ma et al. 2019; Borowczak et al. 2022; Ranjan et al. 2021). This evidence concerns the gene CDK9 and urinary bladder carcinoma.